International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 4 July-Aug 2023, pp: 692-699 www.ijprajournal.com ISSN: 2249-7781

A Review On Sustained Released Matrix Tablet

Hasnain Ali*[1], Indu mittal[1], Mithun kumar[2], Dr. Prabhakar Vishvkarma[3]
[1]-*Department of Pharmacy, IIMT College of medical Sciences, IIMT University Meerut, 250001, Uttar Pradesh, India*
[2]-*Department of Pharmacy, IIMT College of medical Sciences, IIMT University Meerut, 250001, Uttar Pradesh, India*
[3]*Department of Pharmacy, IIMT College of medical Sciences, IIMT University Meerut, 250001, Uttar Pradesh, India*

Submitted: 10-07-2023 Accepted: 20-07-2023

ABSTRACT
In the treatment of chronic conditions, formulations that allow for the prolonged release of drug are quite helpful.
The oral route of administration has identified matrix tablets as the sort of extended drug release that is most likely to be effective. Matrix tablets keep the drug concentration in the plasma constant and keep the rate of drug release consistent throughout the course of the whole treatment period. This allows the tablets to create therapeutic action over an extended period of time. It is essential to use extended-release formulations for treatments that have a low half-life and a high dosing frequency. The rate at which the drug is released may be controlled by the matrix. It is common practice to make use of retardants such as polyglycolic acid, polymethyl methacrylate, and hydroxypropyl methylcellulose (HPMC). The medicament may be found inside the matrix core of the retardant. The matrices that are used might be made of minerals, they can be hydrophobic, or they can be biodegradable. Matrix tablets, which may be created using wet granulation or direct compression methods, have built-in mechanisms that control the release of drugs. These mechanisms make use of a wide variety of polymers. Both a diffusion-controlled method and a dissolution-controlled procedure are used to regulate the release of the drug from matrix tablets. As a consequence of this, matrix tablets boost therapeutic effectiveness while simultaneously cutting down on the number of times a medicine has to be given and improving patient compliance.
Keywords: Sustained release, Matrix Tablets, HPMC, Retardants, Biodegradable

I. INTRODUCTION:

Various terms have been used for defining oral dose forms having changed release features, including controlled or postponed release, prolonged release, repeating action, extended-release, sustained release, and other methods. Every drug delivery technique seeks to halt the regular changes in drug concentration in plasma that happen after using conventional delivery techniques.

Dosages with a modified release: This word refers to medication dosage forms that, in order to accomplish therapeutic and practical aims that conventional dosage forms do not, have distinct course or location characteristics for drug release.

Controlled release: When given, the drug has a zero-order rate of delivery; therefore time has no effect on the concentration that is measured.

Delayed-release: Rather than immediately after administration, a delayed dosage form is designed in order to distribute the medication gradually.

Extended-release: A dosage form is referred to as extended-release if it allows for a lower dosing frequency than that provided by a standard dosage form.

Long-acting: These drugs are administered in a dose form that permits longer-lasting absorption than a conventional dosage form.

Repeat action: The initial dosage is given promptly after intake, followed by the intermittent administration of a second or third dose.

Sustained-release: The method used to distribute the drug regulates how quickly it enters the body.

Since they can take large drug dosages and don't need special manufacturing procedures, sustained release matrix tablets are the best commercially available sustained action drugs.[1-2]

Medication distribution utilizing a sustained-release matrix is an innovative drug delivery system (NDDS) that dramatically improves the therapeutic effectiveness of medications.

New matrix-based formulations with prolonged drug release using readily accessible,

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 4 July-Aug 2023, pp: 692-699 www.ijprajournal.com ISSN: 2249-7781

reasonably priced excipients are currently being pursued.[3] the sustained-release dosage type provided prolonged medicine levels in plasma and often eliminated the need for nocturnal administration, which was favorable for both the patient and the caregiver.

The drug with the desired therapeutic effect is released immediately thanks to the sustained-release formulation. Sustained-release oral medicine administration techniques are becoming more and more common in the pharmaceutical industry.

Furthermore, there is great interest in developing a dosage form that allows for significant drug loading, particularly for medicinal preparations that dissolve well in water. From a business point of view, matrix tablets are believed to be the dosage form with the fewest processing variables included in a prolonged action formulation. [4, 5]

The following are categories of Matrix tablets:

The following categories apply to Matrix's various tablet offerings:

According to the use of compounds that act as retardants:

This category includes the five different kinds of matrix tablets that are listed below:

- **Water-repellent matrix**
- **Lipid matrix**
- **A matrix that adores water**
- **Material biodegradable**

Hydrophobic Matrices

Hydrophobic matrices are often referred to as Plastic Matrices.In this method, the drug is mixed with an inert and/or water-repellent polymer to produce a sustained-release oral dose form. This form of the medication is then crushed into a tablet. This result in a persistent release of the drug that is now dissolving since it has been distributed utilizing a system of channels that remain among the densely packed polymer particles. A few examples of hydrophobic matrices are polyethylene, polyvinyl chloride (PVC), and acrylate polymers, as well as their copolymers. The step of the operation that regulates the pace at which things happen includes the fluid in the matrix being absorbed.

Diffusion is the mechanism that is used for the one-of-a-kind tablet release strategy that this medication utilizes. When matrix tablets are exposed to water and stomach juice, some variants of the tablet lose their ability to function. **[6, 7, and 8]**

Lipid matrices:

In order to construct these matrices, lipid waxes and other compounds with comparable properties are used. These types of materials make it possible for medications to be released into the body via processes such as erosion and pore diffusion. As a consequence of this, the releasing qualities are far more sensitive to the composition of digestive juice when compared to polymer matrices, which are completely insoluble.

Matrices hydrophilic

In order to correctly integrate one or more medications into a matrix (gelling agent), a hydrophilic polymer is used. Water-loving polymer matrices are frequently used in oral controlled drug delivery due to their effectiveness in achieving a desired drug release profile, affordability, and broad regulatory acceptance. These matrices are divided into a further three groups according to the different kinds of polymers that are used in their construction.



Fig 1 Drug Diffusion throughout the Matrix [9]

Cellulose derivatives

Cellulose derivatives are the polymers that are used in the formulation. These polymers include HPMC 100, HEC, and SCMC.

Polymers that are natural or semi-synthetic and are not cellulose, including:

In the category of acrylic acid polymers, the polymer known as Carbopol-934 is the one that sees the greatest use.

Biodegradable Matrices: These polymer contents are made up of single units and operational groupings that are dependent upon one other, and

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 4 July-Aug 2023, pp: 692-699 www.ijprajournal.com ISSN: 2249-7781

their backbones Have Unstable Linkages These matrices deteriorate because they are made up of single units and operational groupings. These substances are then broken down biologically into oligomers and monomers, which are then capable of being digested or released by non-enzymatic processes or by enzymes that are released into the environment in close proximity to live cells.
To provide just a few of examples, there are naturally occurring polymers like proteins and polysaccharides that have been altered.[9, 10]

Material matrix

Polymers generated from a wide variety of seaweed species may be found in mineral matrices. Mineral matrices include these polymers. In mineral matrices, hydrophilic polysaccharides such as alginic acid may be found. This acid can be derived from some species of brown seaweed by treating them with a weak alkali solution.
It depends on the porosity of the matrix, but:
As a consequence of this, the medication is released in a steady stream despite the fact that the drug molecules are dispersed throughout the matrix. The matrix has had an additional three distinct categories added to it.

a) Structures that include macropores
The holes of this particular kind of matrix range in size from 0.1 to 1 m, which makes them much bigger than diffusion molecules. The drug is able to enter this sort of system since it can pass via these pores.

b) Methods that use micropores
Molecules of medicinal value may go through holes with diameters ranging from 50 to 200 nm.

c) Poreless or impermeable systems
These systems are completely devoid of pores. Through the pores and spaces of network meshes, molecular diffusion occurs.
There is no pore phase in the locations where the polymeric phase is present.
Justifications for the creation of the SR matrix DDS 11 include the following:
• To decrease the amount of time between doses,
• To stabilize plasma levels more consistently,
• To allow for more medication consumption,
• To have fewer adverse effects

Extended and Repeated Release Matrix Tablet Benefits:

The formulations that have a sustained release are easier to make, as well as more flexible, efficient, and cost-effective. They also have the potential to maintain therapeutic concentrations for a longer period of time. Finally, using formulations that have a sustained release helps to avoid a high blood concentration.[11-15]

- In spite of this, formulations that have sustained release nevertheless have the potential to boost patient compliance. It is possible to reduce the toxicity of a drug by slowing its absorption.
- Increase the drug's stability by protecting it from the hydrolysis that occurs in the gastrointestinal system as well as any other alterations that are derived from it.
- Attempts should be made to mitigate the adverse effects both locally and systemically.
- An increase in the efficacy of the treatment.
- A reduction in the accumulation of medicine as a result of continued dosing.

POLYMERS USED IN MATRIX TABLET:
Hydrogel
Polyethylene Oxide (PEO), Cross-linked Polyvinyl pyrrolidone (PVP), Polyvinyl Alcohol (PVA), and Polyhydroxyethyl methyl acrylate are the polymers that are used in the matrix tablet.

Soluble polymers
PEG, PVA, PVP, and HPMC (HPMC) are the components.
Examples of polymers include PGA, PCL, and polyanhydrides. Polymers may also have a biological origin.

Non-biodegradable polymers
Ethylcellulose (EC), Cellulose Acetate (CA), Polyvinyl Chloride (PVC), Polyether Urethane (PEU), Polydimethylsiloxane (PDS), Polyethylene Vinyl Acetate (PVA), and Polyvinyl Chloride (PVC) are some of the materials that may be used to make plastic.

Polymers with mucoadhesive properties
- SCMC and Tragacanth.
- Natural gums
- Xanthan gum

A perfect polymer would have the following characteristics: it would be non-toxic, have a high mechanical strength, and be easy to work with. Adaptability and a wide range of properties, including those that are structural,

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 4 July-Aug 2023, pp: 692-699 www.ijprajournal.com ISSN: 2249-7781

physiological, and molecular, would also be desirable.

In addition to being inexpensive and straightforward to produce, it should also be safe for the environment and unreactive to the host's tissue.[16-20]

Several Points to Consider When Choosing Polymers:

- It must be easy to produce the polymer, and it must be soluble. The polymer must have a predetermined number of molecules, and it must be acceptable for use in a biological environment. Finally, the polymer must break down on its own in a natural way.
- It should provide a strong interaction in both the medication and the polymer.

The following characteristics make a drug appropriate for sustained-release tablet formulation:

- The extended-release pill has to meet the ideal pharmacokinetics and physiological requirements, which may be summarized as follows:
- It is required that the atomic size be lower than one thousand Dalton.
- Absorption must take place by diffusion, and neither pH nor catalysts should have any influence on the general absorbability of any GI fragment discharge.
- The half-life of the elimination process should be between 2 and 8 hours.
- Because this decreases the drugs' bioavailability, the metabolic process of drugs shouldn't take place when they are being absorbed.
- The absolute bioavailability should be at least 75%, and achieving a higher value would be preferable.

METHODS FOR THE PREPARATION OF MATRIX TABLETS

1. Wet Granulation Technique

- Milling the excipients and combining the drug, polymer, and medication together using gravity.
- Putting together the mixture for the binder.
- Wet massing, in which a granulating or binder solution is included into the process.
- The process of separating dry particles from wet ones.
- The grains are allowed to dry out.
- Screening done using dry granules.
- The tablet has been crushed. The process of creating "running powder" involves dissolving the ingredients in an emollient while swirling them.

2. The Granulation Process Using Dry

- The grinding and stirring by gravity of the active ingredients, polymer, and inactive ingredients
- Slug or roll compaction, depending on the material
- The pulverizing and screening of powder and slugs that have been compressed.
- Destroying itself after being mixed with lubricant
- The tablet has been made into a more compact form.

3. The Sintering Process

- The formation of a powdery mass is achieved by a process known as sintering, in which neighboring particle surfaces are brought into contact with one another.
- Sintering, in its more traditional form, is accomplished by heating the solid material while maintaining a lower temperature.
- Because of the sintering process, there was a change reported in both the hardness and the time of tablet disintegration when subjected to high temperatures.
- The sintering procedure is used to make sustained release matrix tablets, which are used to maintain the stability of the medication while also delaying its release.

Design Considerations for Dosage Forms

The formulation of the dosage form is primarily determined by two distinct classes of constituents or components. They may be categorized as follows:

1. Biological considerations

a. First-pass effect: Medications that have a substantial first-pass influence have a delayed release rate. This delayed release rate has an effect on the bioavailability of the substance.

b. Half-life: The half-life of a drug is the measurement used to determine how long it remains in the body. If the chemical has a half-life of less than two hours, the dosage method can have an inappropriately high concentration of the medication because of the substance's short half-life. On the other hand, when administered in dosages that are considered standard and utilizing

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 4 July-Aug 2023, pp: 692-699 www.ijprajournal.com ISSN: 2249-7781

drug delivery methods that are continuous, a treatment has a half-life of elimination that is appropriately maintained in the body is eight hours.

c. Adverse effects: There is a possibility that extending the release of the medicine may lead to unintended adverse effects.

d. Absorption and solubility: the concepts of absorbency and soluble are connected to one another. Drugs that are less water soluble might have a negative impact on the overall efficacy of the absorption process.

e. Metabolism: Drugs that undergo considerable processing either in the lumen of the gut or in the tissue prior to absorption may have reduced bioavailability if they are administered in slower-releasing dosage forms. Even if the medication has a low disintegration rate, it is still feasible to create a sustained-release dosage form for it; however, the drug's solubility will need to be improved using the appropriate method before the formulation process can begin. On the other hand, since the medicine is allowed to circulate throughout the body, crystallization of the drug is happening during this period; nevertheless, this should be prevented at all costs because it is potentially harmful.[21-25]

2. Physiochemical factors

a.Drug stability: acidic digestion and breakdown cause pharmaceutical permeability in the digestive system.

b.oral dosage formulations. Solid drugs decay slower than suspended or solution drugs. The most effective control device acts solely in the intestines. Bioavailability of a stomach-poisonous drug may be greatly increased.

c. Aqueous solubility & pKa: A drug that will absorb, dissolve, and partition into the absorbing membrane in water-phase near the delivery site. The drug's water solubility and pKa affect its absorption. These traits make controlled release methods effective. High-aqueous-solubility drugs breakdown slowly and have poor oral bioavailability.

d. Partition Coefficient: The organic phase's medicine-to-water ratio.

Drugs with higher partition co-efficients are unsuitable for oral SRDDS because they won't partition out of the phospholipid membranes. The formula determines it.

K= Co/Cw

Co = Conc. at eqm. in oil.

Cw = equilibrium water concentration.

e. Membrane cavity shape and molecule size impact diffusivity. The flexible polymer array helps intermediate molecular weight pharmaceuticals diffuse at 100–400 Daltons, or 10–6–10–9 cm2/sec. Many polymers have diffusion coefficients below 10–12 cm2/sec for medicines above 500 Daltons. Proteins and peptides are difficult to dose-control.

DRUG RELEASE MECHANISM FROM MATRIX DEVICES:

1) Controlled release for dissolution: Sustained-release oral medicine formulations employ dissolution as the time-limiting phase, making them the simplest to make. Combining medicines is possible. into a slow-dissolving tablet. Rate-limiting phase from the solid item to the bulk solution, the drug diffuses via an unchanged fluid layer. At stable state, the Noyes-Whitney equation will describe dissolution.

KDA(Cs-C) = dc/dt --------- Dissolution control:

Covering pharmaceutical granules or particles with a slow-disintegrating material is this method.

Spacelab's particles are promptly crushed into tablets, whereas spansules' are packed into capsules.

Matrix dissolution:

With a dissolvable carrier, the drug is compacted into tablets. The matrix's porosity, hydrophilic molecules, and tablet and particle surfaces' wettability determine how rapidly the dissolving fluid enters the matrix and makes a medication accessible.[26-30]

Matrix and coated/encapsulated systems

2) Two diffusion-controlled release methods exist:

(a) Regulation of the dispersion of the encapsulant

In this configuration, the active component of the drug is encased in a polymeric material that is insoluble in water. After being partitioned into the polymer membrane, drugs will begin to exchange places with the liquid that surrounds the tablet or powder.

Strategies for Oral Sustained Release Formulation:

(b) Sustained Method Diffusion Release

- Dissolution and Continuous Release
- System Dependent on pH
- System of Alternate Density
- System for osmotic pumps
- Ion Exchange System
- Diffusion sustaining system types: elastic matrix

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 4 July-Aug 2023, pp: 692-699 www.ijprajournal.com ISSN: 2249-7781

- Laminate/Reservoir matrix
.● Dissolution maintained system types:
• System for Matrix Monolith Dissolution.
• Capture, Coating, and Reserve System

EVALUATION OF TABLETS DESIGNED FOR EXTENDED RELEASE:

For the product with sustained release, the development of IVIV studies, as well as the link between the two, is necessary in order to ensure the product's durability, safety, stability, and dependability. The connection between the two also has to be established.

The following criteria for evaluation have been studied at length:

1. Techniques performed in vitro

a. Beakertechnique b. Rotatingdisc procedure c. RotatingBottle technique d. RotatingBasket method e. StationaryBasket technique f. Oscillatingtube process g. Dialysisprocess h. USPdissolution technique.

2. In–vivo Methods

Following the completion of the necessary in-vitro profile, the next step is to design an in-vivo evaluation and IVIVC.

In-vivo assessment may be performed using a variety of methods, some of which are listed below: a. Clinical response; b. Blood level information; c. Blood level information; d. Nourishing study; e. Toxicology research; f. Radioactive tracer technique[31-33]

3. Research Concerning Stability

In order to guarantee the potency, clarity, authenticity, quality, and safety of the medicine as well as the IVIV release speeds that they say up to the time that it is consumed, appropriate stabilizing statistics of the drug and its dose form are required. Additionally, the extended-release drug has to be able to provide the same quantity of the medication at regular intervals, and this quantity can't alter while it's being kept. Acceleration or environmental conditions such as temperature and humidity may have an effect on the in-vitro and in-vivo release rates of the SR drug. The stabilization programming of a sustained-release product is maintained at temperature and humidity conditions that are both standard and quick. This ensures that the material can endure the conditions that it will be exposed to in the future.

4. Bioavailability Testing:

The term "bioavailability" refers to a specific medication moiety, which is often an active pharmaceutical component. This medication moiety might either be the medicine in its natural state or a metabolite, such as in the case of prodrugs. The net flow of drug-related material from the site of administration into the body is often referred to as "absorption," and the term "absorption" is commonly used to characterize this movement. The adjustment of the therapeutic dose form can be required in order to improve the absorption qualities of the medication and, as a consequence, its bioavailability. Studies of bioavailability generally compare the tested medicinal product when it is administered as a single dosage to healthy participants who are fasting. [34-35]

II. CONCLUSION

This review research focused mostly on the composition of long-lasting matrices tablets, as well as their advantages and disadvantages, and the many polymers that were used to build a technique. The previous discussion has led us to the conclusion that the matrix tablets are effective in overcoming patient compliance concerns as well as issues related to the efficiency of the dosage form. These issues are connected to the failure of traditional dosage forms to provide the necessary therapeutic response. In addition to its numerous benefits, one of the pluses is that it may either be consumed all at once or on a daily basis. Because of this, the design of the dosage form is now being optimized to produce sustained-release matrix tablets. [36-40]

REFERENCES

[1]. Gupta PK and Robinson JR. Oral controlled release delivery. Treatise on controlled drug delivery. 1992;93(2):545-555.
[2]. Jantzen GM and Robinson JR. Sustained and Controlled- Release Drug Delivery systems. Modern Pharmaceutics. 1995; 121(4): 501-502.
[3]. Altaf AS, Friend DR, MASRx and COSRx Sustained-Release Technology in Rathbone MJ, Hadgraft J, and Robert MS. Modified Release Drug Delivery Technology, Marcel Dekker Inc., New York, 2003; 126: 996.
[4]. Gwen MJ and Joseph RR, In Banker GS and Rhodes CT, Eds. Modern

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 4 July-Aug 2023, pp: 692-699 www.ijprajournal.com ISSN: 2249-7781

Pharmaceutics, Marcel Dekker Inc. New York, 1996; 72(3): 575.

[5]. Salsa T, Veiga F and Pina ME. Oral controlled release dosage form. I. cellulose ether polymers in hydrophilic matrices. Drug Develop. Ind. Pharm. 1997; 23: 929-938.

[6]. Wani MS et al. Controlled Release system-A Review. Pharmaceutical Reviews. 2008; 6(1): 41-46.

[7]. Altaf AS, Friend DR, MASRx and COSRx Sustained-Release Technology in Rathbone MJ, Hadgraft J, Robert MS, Modified Release Drug Delivery Technology, Marcell Dekker Inc., New York, 2003. JPSBR: Volume 1, Issue 3: Nov Dec 2011 (143-151) Patel H. 151

[8]. Vidyadhara S, Rao PR, Prasad JA. Formulation And Evaluation Of Propranolol Hydrochloride Oral Controlled Release Matrix Tablets. Indian J.Pharm Sci, 2004; 66: 188-192.

[9]. Reddy KR, Mutalik S, Reddy S. Once-daily sustained release matrix tablets of Nicorandil: Formulation and in vitro evaluation,AAPS Pharm. Sci. Tech.,2003; 4: 1-9.

[10]. Mohammed AD, James LF, Michael HR, John EH, Rajabi-Siahboomi AR. Release of Propranolol hydrochloride from matrix tablets containing sodium carboxy methylcellulose and Hydroxy propyl methyl cellulose. Phar. Dev. Tech.,1999; 4: 313-324.

[11]. Lee BJ, Ryu SG, Cui JH. Formulation and release characteristics of hydroxypropyl methylcellulose matrix tablet containing melatonin. Drug Dev. Ind.Pharm.,1999; 25: 493-501.

[12]. Gwen MJ, Joseph RR, In Banker GS and Rhodes CT, Eds., Modern Pharmaceutics, 3rd Edn, Vol. 72, Marcel Dekker Inc. New York, 1996: 575.

[13]. Borguist P, Korner A, Larsson A: A model for the drug release from a polymeric matrix tablets-effect of swelling and dissolution. J Controlled Release 2006; 113: 216-225.

[14]. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Dev Rev 2001; 48:139-157.

[15]. http://dissertations.ub.rug.nl/Files/faculties /sci ence/2005/r.steendam/c2.pdf(5Aug, 2006).

[16]. Reza MS, Quadir MA, Haider SS. Comparative evaluation of plastic, hydrophobic and hydrophilic polymers as matrices for controlled release drug delivery. J Pharm Pharmaceut Sci 2003; 6 (2): 282-291. 17.Brazel CS, Peppas NA. Dimensionless analysis of swelling of hydrophilic glassy polymers with subsequent drug release from relaxing structures. Biomaterials 1999 Apr; 20 (8): 721- 732.

[17]. Brazel CS, Peppas NA. Modeling of drug release from swellable polymers. Eur J Pharm Biopharm 2000 Jan; 49 (1): 47-58.

[18]. http://dissertations.ub.rug.nl/Files/faculties /scie nce/2005/r.steendam/c2.pdf(5Aug, 2006).

[19]. Hariharan M, Wheatley TA, Price JC. Controlled release tablet matrices from carrageenans: compression and dissolution studies. Pharm Dev Technol 1997; 2(4): 383– 393.

[20]. Takka S, Rajbhandari S, Sakr A. Effect of anionic polymers on the release of propranolol hydrochloride from matrix tablets. Eur J Pharm Biopharm 2001; 52:75-82.

[21]. Alderman DA. Review of cellulose ethers in hydrophilic matrices for oral controlled-release dosage form. Int. J. Pharm. Technol. Prod. Mfr. 1984; 5: 1-9.

[22]. Melia CD. Hydrophilic matrix sustained release systems 395- based on polysaccharide carriers. Crit. Rev. Ther. Drug Carrier Sys. 1991; 8(4): 421.

[23]. Aulton Michael .E, The Design and Manufacture of Medicines, Church Hill Living Stone Vol. 3, 2007: 483-494.

[24]. Jantzen GM, Robinson JR, Sustained and controlled-release drug delivery systems, in Banker GS, Rhodes CT (Eds.) Modern Pharmaceutics, Third Edition, Revised and Expanded, Drugs and the Pharmaceutical Sciences, vol 72, Marcell Dekker, Inc. New York, 1995: 575-609.

[25]. Alford N Martin, Patrick J. Sinko. Martin's Physical pharmacy and pharmaceutical sciences, 2006.

[26]. L. Lachman, HA Lieberman, Joseph L Kanig. The theory and practice of Industrial pharmacy, Verghesh publishing house, 3rd edition, 1990; 346.

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 4 July-Aug 2023, pp: 692-699 www.ijprajournal.com ISSN: 2249-7781

[27]. mamidala RK, Ramana V, sandeep G, "Factors influencing the design and performance of oral, sustained /controlled Release dosage forms" UPSN,2009,S83-S86.
[28]. Leon S, Susanna W, Andrew BC , "Applied Biopharmaceutics and Pharmacokinetics", 5th edition McGraw-Hill's Access Pharmacy, 2004, 17.1-17.9.
[29]. Sayed I. Abdel-Rahman, Gamal MM, El-Badry M, Preparation and comparative evaluation of sustained release metoclopramide hydrochloride matrix tablets, Saudi Pharmaceutical Journal ,2009 ; 17: 283-288.
[30]. Chandran S, Laila FA and Mantha N, Design and evaluation of Ethyl Cellulose Based Matrix Tablets of Ibuprofen with pH Modulated Release Kinetics, Indian Journal of Pharmaceutical Sciences, September-October 2008.
[31]. Gothi GD, Parinh BN, Patel TD, Prajapati ST, Patel DM, Patel CN, Journal of Global Pharma Technology, 2010; 2(2): 69-74.
[32]. Aulton Michael .E, The Design and Manufacture of Medicines, Church Hill Living Stone Vol. 3, 2007: 483-494.
[33]. Shargel L, Yu ABC. Modified release drug products. In: Applied Biopharmaceutics and Pharmacokinetics. 4th edition, 1999: 169-171.
[34]. Muzib Y.Indira, Padma Sree.Kurri: Formulation and evaluation of gum olibanumbased sustained release matrix tablets of Ambroxol hydrochloride. International Journal of Pharmacy and Pharmaceutical Sciences 2011; 3(2): 195-199.
[35]. Vyas SP, Khar RK. Controlled Drug Delivery: Concepts and Advances. Ist ed. vallabh prakashan, 2002:156-189.
[36]. Brahmankar HA, Jaiswal SB. Biopharmaceutics and Pharmacokinetics A Treatise, Vallabh Prakashan, 2000, 348-357 and 337.
[37]. Venkatraman S, Davar A, Chester A, Kleiner L, Wise DL. An overview of controlled release systems, Handbook of Pharmaceutical Controlled Release Technology, New York, Marcel Dekker, Inc.,2000, 431-465.
[38]. Sriwongjanya M and Bodmeier R. Entrapment of drug loaded ion exchange particles within polymeric microparticles. Int. J. Pharm. 1988; 48: 217-222.
[39]. Brahmankar HA, Jaiswal SB, Biopharmaceutics and Pharmacokinetics A Treatise, Vallabh Prakashan, 2000, 348-357 and 337.